A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)-Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis
Summary:
| HR#: |
18530 |
| PRINCIPAL INVESTIGATOR: |
, |
| SPONSOR: |
|
| TARGET ENROLLMENT: |
10 |
| DISEASE TYPE: |
Pancreatitis |
| BODY LOCATION(S): |
Pancreas, |
| PRIMARY OBJECTIVE: |
To demonstrate that RG1068-enhanced MRCP improves sensitivity in the detection of pancreatic duct abnormalities compared to unenhanced MRCP without loss of specificity, using an ERCP-based truth standard |
| SECONDARY OBJECTIVE(S): |
|
| INCLUSION CRITERIA: |
|
| EXCLUSION CRITERIA: |
|
| TREATMENT GROUPS: |
|
| LENGTH OF STUDY: |
|
| CONTACTS: |
- , (Primary Study Coordinator)
or
- Kyle Orrell, MSHP (DDC Research Program Manager)
843-876-4303 or orrell@musc.edu
- , (Principal Investigator)
or
|
|